Studies on preparation of recombinant hirudin-2 liposome and its pharmacokinetics by nasal delivery in rats
Research article published in Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica (2007)
Abstract
OBJECTIVE: To promote the nasal absorption of recombinant hirudin-2, the preparation and physicochemical properties of recombinant hirudin-2 liposomes, as well as its pharmacokinetic characteristics and bioavailability in rats after nasal administration were investigated. METHOD: Recombinant hirudin-2 liposomes were prepared by reversal phase evaporation; the test of physicochemical properties including encapsulation efficiency, particle size and stability of liposome suspensions were determined by HPLC; Recombinant hirudin-2 concentration in plasma was determined by chromogenic substrate method and the relative bioavailability and pharmacokinetic parameters were also calculated using software program 3p87. RESULT: The encapsulation efficiency of recombinant hirudin-2 liposome reached greater than 76.95%, with an average particle size of about 168.3 nm, size distribution ranging from 24 to 286 nm, relative peak width of +/- 0.47, and a good stability. CONCLUSION: Compared with recombinant hirudin-2 solution, liposome preparation enhanced the nasal absorption of recombinant hirudin-2.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Zusammenfassung
To promote the nasal absorption of recombinant hirudin-2, the preparation and physicochemical properties of recombinant hirudin-2 liposomes, as well as its pharmacokinetic characteristics and bioavailability in rats after nasal administration were investigated.
Warum dies für die Hirudotherapie relevant ist
This study examined the preparation, physicochemical properties, and pharmacokinetics of recombinant hirudin-2 liposomes after nasal administration in rats. Prepared by reversal phase evaporation, the liposomes achieved encapsulation efficiencies above 76.95%, an average particle size of approximately 168.3 nm with good stability, and enhanced nasal absorption compared with recombinant hirudin-2 solution. This may be relevant to ASH's domain as it explores an alternative delivery route for hirudin, a peptide widely recognized as a leech-derived anticoagulant central to hirudotherapy, although the abstract itself does not mention leech origin. This is a preclinical animal pharmacokinetic study with no clinical data; no leeches or hirudotherapy are directly involved.
Zitation
Verwandter klinischer Kontext
Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist
Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026